China Medical Systems In-Licenses Respiratory Distress Drug From Faron Pharmaceuticals Ltd.
China Medical Systems, headquartered in Shenzhen, in-licensed greater China rights to Traumakine®, a treatment for moderate to severe acute respiratory distress syndrome (ARDS) from Faron Pharma, a Finnish virtual biopharma. At the same time, A&B Ltd., a company owned by Dr. Kong Lam, the CEO of China Medical Systems, made a $5.5 million investment in Faron. A&B will also underwrite the costs of regulatory approval in China.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.